ClinicalTrials.gg
RecruitingNCT06819007DO-01Updated Oct 28, 2026

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

A Phase 3 interventional study of Trastuzumab Deruxtecan and Bevacizumab in Ovarian Cancer, sponsored by Daiichi Sankyo. Recruiting at 232 sites in 26 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 28, 2026First site in GermanyEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Ovarian Neoplasms by Daiichi Sankyo — 5 open to participants now, 6 under way, 3 of them phase 3. Ovarian Neoplasms · Daiichi Sankyo.

Started
2025
with 1 other
Phase 3
2 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Ovarian Neoplasms by Daiichi Sankyo, this one is one of 2 that started in 2025, is one of 2 in phase 3, and was the 10th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 12 studies in Ovarian Neoplasms by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ovarian Neoplasms by Daiichi Sankyo, or all of them as a file.
02

Study summary

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Read the detailed description

A non-randomized safety run-in phase will be conducted prior to randomization phase to assess the safety of T-DXd in combination with bevacizumab.

03

Conditions studied

  • Ovarian Cancer

Keywords

  • Ovarian cancer
  • epithelial ovarian cancer
  • HER2
  • Trastuzumab Deruxtecan
  • Bevacizumab
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Sign and date the tissue prescreening form (ICF), prior to central testing. Sign and date the Main ICF prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures.

    *For participants in the safety run-in phase, a safety run-in ICF needs to be signed and dated prior to the start of any trial-specific qualification procedures.

  2. Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old.
  3. Has confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma per local assessment (including but not limiting to serous, endometrioid, clear cell, carcinosarcoma, mucinous).
  4. Is newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV.
  5. Has HER2 expression.

Key Exclusion Criteria:

  1. Has ovarian, fallopian tube, or peritoneal cancer of non-epithelial origin.
  2. Has a known or suspected deleterious BRCA alteration as per local test that makes the participant eligible for poly (ADP-ribose) polymerase (PARP) inhibitor.
  3. Participant to receive PARP inhibitor as maintenance per standard of care and investigator discretion.
  4. Previous cerebral-vascular accident, or subarachnoid hemorrhage within 6 months prior to randomization.

    *Note: For participants enrolled from the Republic of Korea, country-specific requirements are applicable.

  5. Has evidence of bleeding diathesis or significant coagulopathy (in the absence of anticoagulation therapy).
  6. Has a history of hemorrhagic disorders.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
582 participants (estimated)

Study arms

  • Experimental
    Treatment Arm A

    Participants will receive T-DXd in combination with bevacizumab.

    Drug: Trastuzumab Deruxtecan · Drug: Bevacizumab

  • Active comparator
    Treatment Arm B

    Participants will receive bevacizumab monotherapy.

    Drug: Bevacizumab

Interventions

  • T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W).

    Also known as: T-DXd, ENHERTU®

  • Bevacizumab will be administered at a dose of 15 mg/kg IV Q3W.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ Population

    Time from randomization to time of objective radiographic disease progression as assessed by BICR based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or death due to any cause.

    Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months

Secondary outcomes

  1. Overall Survival (OS) in the HER2 IHC 3+/2+ Population

    Time interval from the date of randomization to the date of death due to any cause.

    Time frame: From date of randomization to death due to any cause, up to approximately 72 months

  2. PFS by BICR in the HER2 IHC 3+/2+/1+ Population

    Time from randomization to time of objective radiographic disease progression as assessed by BICR based on RECIST v1.1 or death due to any cause.

    Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months

  3. OS in the HER2 IHC 3+/2+/1+ Population

    Time interval from the date of randomization to the date of death due to any cause.

    Time frame: From date of randomization to death due to any cause, up to approximately 72 months

  4. PFS by the Investigator in HER2 IHC 3+/2+ Population

    Time from randomization to time of objective radiographic disease progression as assessed by the investigator based on RECIST v1.1 or death due to any cause.

    Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months

  5. PFS by the Investigator in HER2 IHC 3+/2+/1+ Population

    Time from randomization to time of objective radiographic disease progression as assessed by the investigator based on RECIST v1.1 or death due to any cause.

    Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months

  6. Progression Free Survival 2 (PFS2) by the Investigator in HER2 IHC 3+/2+ Population

    Time from date of randomization to the first documented progression on subsequent systemic therapy by investigator assessment, or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months

  7. PFS2 by the Investigator in HER2 IHC 3+/2+/1+ Population

    Time from date of randomization to the first documented progression on subsequent systemic therapy by investigator assessment, or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months

  8. Confirmed Objective Response (OR) by BICR in HER2 IHC 3+/2+ Population

    OR is defined as participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) assessed by BICR according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  9. Confirmed OR by the Investigator in HER2 IHC 3+/2+ Population

    OR is defined as participants with BOR of confirmed CR or confirmed PR assessed by the investigator, according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  10. Confirmed OR by BICR in HER2 3+/2+/1+ Population

    OR is defined as participants with BOR of confirmed CR or confirmed PR as assessed by BICR according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  11. Confirmed OR by the Investigator in HER2 IHC 3+/2+/1+ Population

    OR is defined as participants with BOR of confirmed CR or confirmed PR assessed by the investigator, according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  12. Duration of Response (DoR) by BICR in HER2 IHC 3+/2+ Population

    Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by BICR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  13. DoR by the Investigator in HER2 IHC 3+/2+ Population

    Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by investigator, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  14. DoR by BICR in HER2 IHC 3+/2+/1+ Population

    Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by BICR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  15. DoR by the Investigator in HER2 IHC 3+/2+/1+ Population

    Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by investigator, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 35 months

  16. Time to First Subsequent Treatment (TFST) in HER2 IHC 3+/2+ Population

    Time from randomization until the start date of the first subsequent anticancer therapy after discontinuation of randomized treatment, or death due to any cause.

    Time frame: Up to approximately 72 months

  17. TFST in HER2 IHC 3+/2+/1+ Population

    Time from randomization until the start date of the first subsequent anticancer therapy after discontinuation of randomized treatment, or death due to any cause.

    Time frame: Up to approximately 72 months

  18. Time to Second Subsequent Treatment (TSST) in HER2 IHC 3+/2+ Population

    Time from randomization until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

    Time frame: Up to approximately 72 months

  19. TSST in HER2 3+/2+/1+ Population

    Time from randomization until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

    Time frame: Up to approximately 72 months

  20. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as those AEs with start or worsening date during the on-treatment period (from the first dose date of trial intervention to 47 days after the last dose date of trial intervention).

    Time frame: Up to approximately 82 months

  21. Change from Baseline in Physical Function from European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30)

    The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The physical functional scale is scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). Scores are linearly transformed on a scale of 0 to 100. A higher scale score represents better functioning.

    Time frame: Baseline up to approximately 72 months

  22. Change from Baseline in Pain from EORTC QLQ-C30

    The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The pain symptom scale is scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). Scores are linearly transformed on a scale of 0 to 100. A higher scale score represents worse symptom.

    Time frame: Baseline up to approximately 72 months

  23. Change from Baseline in Global Health Status/Overall Quality of Life (GHS/Overall QoL) Scales from EORTC QLQ-C30

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status.

    Time frame: Baseline up to approximately 72 months

  24. Change from Baseline in Abdominal/Gastrointestinal (GI) Symptoms from EORTC Quality of Life Questionnaire Ovarian Cancer Module 28 (QLQ-OV28)

    EORTC QLQ-OV28 is an ovarian cancer-specific module to supplement the EORTC QLQ-C30. Participant responses to the 6 abdominal/GI symptoms scale questions are scored on a 4-point scale (1=not at all, 4=very much). The combined score is computed by averaging the raw scores of the 6 items and then applying a linear transformation to standardize the average score, so that the combined score ranges from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-OV28 Items 31-36) score will be presented. A lower score indicates a better outcome.

    Time frame: Baseline up to approximately 72 months

  25. Percentage of Participants With Confirmed Deterioration for Physical function, Pain, GHS/Overall QoL scales from EORTC QLQ-C30

    The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The functional, symptom, and single items are scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). The final 2 global health/QoL items are scored on a 7-point scale ranging from 1 ("very poor") to 7 ("excellent"). All of the scales and single-item measure scores are linearly transformed on a scale of 0 to 100. A higher scale score represents a higher response level and worse symptoms for the symptom scales.

    Time frame: Up to approximately 72 months

  26. Percentage of Participants With Confirmed Deterioration Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28

    EORTC QLQ-OV28 is an ovarian cancer-specific module to supplement the EORTC QLQ-C30. Participant responses to the 6 abdominal/GI symptoms scale questions are scored on a 4-point scale (1=not at all, 4=very much). The combined score is computed by averaging the raw scores of the 6 items and then applying a linear transformation to standardize the average score, so that the combined score ranges from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-OV28 Items 31-36) score will be presented. A lower score indicates a better outcome.

    Time frame: Up to approximately 72 months

  27. Time to Confirmed Deterioration for Physical Function, Pain, GHS/Overall QoL Scales from EORTC QLQ-C30

    The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The functional, symptom, and single items are scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). The final 2 global health/QoL items are scored on a 7-point scale ranging from 1 ("very poor") to 7 ("excellent"). All of the scales and single-item measure scores are linearly transformed on a scale of 0 to 100. A higher scale score represents a higher response level and worse symptoms for the symptom scales.

    Time frame: Up to approximately 72 months

  28. Time to Confirmed Deterioration for Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28

    EORTC QLQ-OV28 is an ovarian cancer-specific module to supplement the EORTC QLQ-C30. Participant responses to the 6 abdominal/GI symptoms scale questions are scored on a 4-point scale (1=not at all, 4=very much). The combined score is computed by averaging the raw scores of the 6 items and then applying a linear transformation to standardize the average score, so that the combined score ranges from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-OV28 Items 31-36) score will be presented. A lower score indicates a better outcome.

    Time frame: Up to approximately 72 months

07

Study locations

232 of 232 sites recruiting

Showing the first 100 of 232 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 43 months is close to that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 11, 2025
StartActual
Mar 19, 2025
Primary completionEst.
Nov 1, 2028
CompletionEst.
Jan 31, 2032
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
38 sites added, 14 sites removed — first site in Germany
Show 38 added (11 Germany, 6 Japan, 5 Spain, 3 China, 2 Australia, 2 Hungary, 2 Italy, 2 Malaysia, 1 United States, 1 Brazil, 1 India, 1 Israel, 1 Taiwan)
  • University of Wisconsin · Madison, United States
  • Sir Charles Gairdner Hospital · Perth, Australia
  • Epworth Healthcare · Richmond, Australia
  • Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto · São José do Rio Preto, Brazil
  • Women's Hospital School of Medicine Zhejiang University · Hangzhou, China
  • Harbin Medical University - Tumor Hospital · Harbin, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
  • Charite-Universitatsmedizin · Berlin, Germany
  • Universitaetsklinikum Bonn · Bonn, Germany
  • Klinikum Lippe GmbH · Detmold, Germany
  • Universitatsklinikum Hamburg-Eppendorf · Hamburg, Germany
  • SLK-Kliniken Heilbronn GmbH · Heilbronn, Germany
  • Universitatsklinikum Jena · Jena, Germany
  • University Medical Center Mannheim · Mannheim, Germany
  • Philipps-Universitat Marburg · Marburg, Germany
  • Univeristy Regensburg, Caritas-Krankenhaus St. Josef · Regensburg, Germany
  • Universitaetsklinikum Ulm · Ulm, Germany
  • Helios Dr. Horst Schmidt Kliniken Wiesbaden · Wiesbaden, Germany
  • Semmelweis Egyetem · Budapest, Hungary
  • Orszagos Onkologiai Intezet Nogyogyaszati Osztaly · Budapest, Hungary
  • Vardhman Mahavir Medical College & Safdarjung Hospital · Delhi, India
  • Sheba Medical Center · Tel HaShomer, Israel
  • Azienda Socio Sanitaria Territoriale Niguarda · Milan, Italy
  • Arcispedale S. Maria Nuova Azienda Ospedaliera Di Reggio Emilia · Reggio Emilia, Italy
  • Iwate Medical University Hospital · Yahaba-cho, Japan
  • Saitama Medical University International Medical Center · Hidaka, Japan
  • Kurume University Hospital · Kurume, Japan
  • Shizuoka Cancer Center · Nakatogari, Japan
  • Kindai University Hospital · Osaka, Japan
  • National Cancer Center Hospital · Tokyo, Japan
  • …and 8 more on the registry record
Show 14 removed
  • Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto · Sao Jose Rio, Brazil
  • Harbin Medical University - Tumor Hospital · Haerbing, China
  • Women's Hospital School of Medicine Zhejiang University · Hangzhoushi, China
  • Fudan University Shanghai Cancer Center · Shanghai Shi, China
  • Sheba Medical Center · Tel Litwinsky, Israel
  • National Cancer Center Hospital · Chūōku, Japan
  • Saitama Medical University International Medical Center · Hidaka-Shi, Japan
  • Kurume University Hospital · Kurume-shi, Japan
  • Kindai University Hospital · Osakasayama-shi, Japan
  • Iwate Medical University Hospital · Shiwa-Gun, Japan
  • Shizuoka Cancer Center · Sunto-gun, Japan
  • HOSPITAL KUALA LUMPUR(HKL) Kuala · Lumpur, Malaysia
  • Hospital Universitario Donostia · Planta Baja, Spain
  • Chang Gung Memorial Hospital · Linkou Taoyuan, Taiwan
Oct 28, 2026
Eligibility
7 criteria edited, 2 added, 18 removed
What changed in the criteria
  • EditedSign and date the tissue prescreening informed consent form (ICF), prior to HER2 central testing. Sign and date the Main ICF, prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures.
  • EditedHas histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma per local assessment (including but not limiting to serous, endometrioid, clear cell, carcinosarcoma, mucinous).
  • EditedIs newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV.
  • RemovedHas HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+/2+/1+) guidelines1 by prospective central testing.
  • Removed*For participants in the safety run-in phase, HER2 expression assessed by either local (require using ASCO-CAP gastric cancer IHC scoring [IHC 3+/2+/1+] guidelines) or central assessment (if available) is acceptable. Submission of the pathology report is required for participants enrolled based on local HER2 IHC results.
  • RemovedHas adequate tumor tissue sample available for assessment of HER2 by central laboratory. Tumor tissue block or sufficient tissue slides are required for HER2 testing and retrospective HRD status determination.
  • Removed*Participants in the safety run-in phase who are enrolled based on local HER2 IHC results are recommended to provide tumor tissue sample from the same specimen for central assessment.
  • RemovedHas a local HRD or BRCA test result available. Participants with BRCA-wildtype will have a local HRD test results, as applicable.
  • RemovedHas received up to 6 cycles of standard of care bevacizumab in combination with frontline platinum- based chemotherapy as per approved indication and clinical guidelines and is eligible to continue single agent bevacizumab maintenance per standard of care and investigator discretion.
  • AddedHas HER2 expression.
  • EditedHas a known or suspected deleterious BRCA alteration as per local test that makes the patientparticipant eligible for poly (ADP-ribose) polymerase (PARP) inhibitor.
  • EditedParticipant to receive PARP inhibitor as maintenance per standard of care and investigator discretion. Reasons for which the participant is not eligible for PARP inhibitor will be recorded in the eCRF as follows:
  • RemovedHRD negative
  • RemovedHRD positive with SD as best response after platinum
  • RemovedHRD positive non-serous histology Note: For participants enrolled from the Republic of Korea
  • RemovedHRD tested, but inconclusive
  • RemovedHRD positive but safety concern (safety concern to be specified).
  • RemovedHas a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug products and other monoclonal antibodies.
  • EditedPrevious Cerebralcerebral-Vascular Accidentvascular accident, Transient Ischemic Attacktransient ischemic attack or Sub- Arachnoids Hemorrhagesubarachnoid hemorrhage within 6 months prior to randomization.
  • Edited*Note: For participants enrolled from the Republic of Korea, country-specific requirements are applicable.
  • RemovedHas a history of hemorrhagic disorders, abdominal fistula, gastrointestinal perforation, or active gastrointestinal bleeding within 6 months before randomization.
  • RemovedEvidence of active or ongoing bowel obstruction.
  • RemovedHas a medical history of myocardial infarction within 6 months before randomization, symptomatic congestive heart failure (New York Heart Association Class II to IV).
  • RemovedParticipants with troponin levels above the upper limit of normal at Screening (as defined by the manufacturer), and without any myocardial infarction related symptoms should have a cardiologic consultation during the Screening Period to rule out myocardial infarction.
  • RemovedHas a corrected QT interval prolongation to >480 msec based on average of the Screening triplicate 12-lead ECG.
  • RemovedHas a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  • AddedHas a history of hemorrhagic disorders.
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProgression Free Survival (PFS) by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
Oct 28, 2026
Secondary outcomes
5 edited, 23 added
What changed in the outcomes
  • EditedOverall Survival (OS) in the HER2 IHC 3+/2+ populationPopulationTime frame: From date of randomization to death due to any cause, up to approximately 72 months
  • EditedProgression Free SurvivalPFS by BICR in the HER2 IHC 3+/2+/1+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
  • EditedOverall SurvivalOS in the HER2 IHC 3+/2+/1+ populationPopulationTime frame: From date of randomization to death due to any cause, up to approximately 72 months
  • EditedProgression Free SurvivalPFS by the investigatorInvestigator in HER2 IHC 3+/2+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
  • EditedProgression Free SurvivalPFS by the investigatorInvestigator in HER2 IHC 3+/2+/1+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
  • AddedProgression Free Survival 2 (PFS2) by the Investigator in HER2 IHC 3+/2+ PopulationTime frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months
  • AddedPFS2 by the Investigator in HER2 IHC 3+/2+/1+ PopulationTime frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months
  • AddedConfirmed Objective Response (OR) by BICR in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
  • AddedConfirmed OR by the Investigator in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
  • AddedConfirmed OR by BICR in HER2 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
  • AddedConfirmed OR by the Investigator in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
  • AddedDuration of Response (DoR) by BICR in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
  • AddedDoR by the Investigator in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
  • AddedDoR by BICR in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
  • AddedDoR by the Investigator in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
  • AddedTime to First Subsequent Treatment (TFST) in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 72 months
  • AddedTFST in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 72 months
  • AddedTime to Second Subsequent Treatment (TSST) in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 72 months
  • AddedTSST in HER2 3+/2+/1+ PopulationTime frame: Up to approximately 72 months
  • AddedNumber of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 82 months
  • AddedChange from Baseline in Physical Function from European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30)Time frame: Baseline up to approximately 72 months
  • AddedChange from Baseline in Pain from EORTC QLQ-C30Time frame: Baseline up to approximately 72 months
  • AddedChange from Baseline in Global Health Status/Overall Quality of Life (GHS/Overall QoL) Scales from EORTC QLQ-C30Time frame: Baseline up to approximately 72 months
  • AddedChange from Baseline in Abdominal/Gastrointestinal (GI) Symptoms from EORTC Quality of Life Questionnaire Ovarian Cancer Module 28 (QLQ-OV28)Time frame: Baseline up to approximately 72 months
  • AddedPercentage of Participants With Confirmed Deterioration for Physical function, Pain, GHS/Overall QoL scales from EORTC QLQ-C30Time frame: Up to approximately 72 months
  • AddedPercentage of Participants With Confirmed Deterioration Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28Time frame: Up to approximately 72 months
  • AddedTime to Confirmed Deterioration for Physical Function, Pain, GHS/Overall QoL Scales from EORTC QLQ-C30Time frame: Up to approximately 72 months
  • AddedTime to Confirmed Deterioration for Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28Time frame: Up to approximately 72 months
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    38 sites added, 14 sites removed — first site in Germany
    Show 38 added (11 Germany, 6 Japan, 5 Spain, 3 China, 2 Australia, 2 Hungary, 2 Italy, 2 Malaysia, 1 United States, 1 Brazil, 1 India, 1 Israel, 1 Taiwan)
    • University of Wisconsin · Madison, United States
    • Sir Charles Gairdner Hospital · Perth, Australia
    • Epworth Healthcare · Richmond, Australia
    • Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto · São José do Rio Preto, Brazil
    • Women's Hospital School of Medicine Zhejiang University · Hangzhou, China
    • Harbin Medical University - Tumor Hospital · Harbin, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    • Charite-Universitatsmedizin · Berlin, Germany
    • Universitaetsklinikum Bonn · Bonn, Germany
    • Klinikum Lippe GmbH · Detmold, Germany
    • Universitatsklinikum Hamburg-Eppendorf · Hamburg, Germany
    • SLK-Kliniken Heilbronn GmbH · Heilbronn, Germany
    • Universitatsklinikum Jena · Jena, Germany
    • University Medical Center Mannheim · Mannheim, Germany
    • Philipps-Universitat Marburg · Marburg, Germany
    • Univeristy Regensburg, Caritas-Krankenhaus St. Josef · Regensburg, Germany
    • Universitaetsklinikum Ulm · Ulm, Germany
    • Helios Dr. Horst Schmidt Kliniken Wiesbaden · Wiesbaden, Germany
    • Semmelweis Egyetem · Budapest, Hungary
    • Orszagos Onkologiai Intezet Nogyogyaszati Osztaly · Budapest, Hungary
    • Vardhman Mahavir Medical College & Safdarjung Hospital · Delhi, India
    • Sheba Medical Center · Tel HaShomer, Israel
    • Azienda Socio Sanitaria Territoriale Niguarda · Milan, Italy
    • Arcispedale S. Maria Nuova Azienda Ospedaliera Di Reggio Emilia · Reggio Emilia, Italy
    • Iwate Medical University Hospital · Yahaba-cho, Japan
    • Saitama Medical University International Medical Center · Hidaka, Japan
    • Kurume University Hospital · Kurume, Japan
    • Shizuoka Cancer Center · Nakatogari, Japan
    • Kindai University Hospital · Osaka, Japan
    • National Cancer Center Hospital · Tokyo, Japan
    • …and 8 more on the registry record
    Show 14 removed
    • Fundacao Faculdade Regional De Medicina De Sao Jose Do Rio Preto · Sao Jose Rio, Brazil
    • Harbin Medical University - Tumor Hospital · Haerbing, China
    • Women's Hospital School of Medicine Zhejiang University · Hangzhoushi, China
    • Fudan University Shanghai Cancer Center · Shanghai Shi, China
    • Sheba Medical Center · Tel Litwinsky, Israel
    • National Cancer Center Hospital · Chūōku, Japan
    • Saitama Medical University International Medical Center · Hidaka-Shi, Japan
    • Kurume University Hospital · Kurume-shi, Japan
    • Kindai University Hospital · Osakasayama-shi, Japan
    • Iwate Medical University Hospital · Shiwa-Gun, Japan
    • Shizuoka Cancer Center · Sunto-gun, Japan
    • HOSPITAL KUALA LUMPUR(HKL) Kuala · Lumpur, Malaysia
    • Hospital Universitario Donostia · Planta Baja, Spain
    • Chang Gung Memorial Hospital · Linkou Taoyuan, Taiwan
    Eligibility 7 criteria edited, 2 added, 18 removed
    What changed in the criteria
    • EditedSign and date the tissue prescreening informed consent form (ICF), prior to HER2 central testing. Sign and date the Main ICF, prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures.
    • EditedHas histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma per local assessment (including but not limiting to serous, endometrioid, clear cell, carcinosarcoma, mucinous).
    • EditedIs newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV.
    • RemovedHas HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+/2+/1+) guidelines1 by prospective central testing.
    • Removed*For participants in the safety run-in phase, HER2 expression assessed by either local (require using ASCO-CAP gastric cancer IHC scoring [IHC 3+/2+/1+] guidelines) or central assessment (if available) is acceptable. Submission of the pathology report is required for participants enrolled based on local HER2 IHC results.
    • RemovedHas adequate tumor tissue sample available for assessment of HER2 by central laboratory. Tumor tissue block or sufficient tissue slides are required for HER2 testing and retrospective HRD status determination.
    • Removed*Participants in the safety run-in phase who are enrolled based on local HER2 IHC results are recommended to provide tumor tissue sample from the same specimen for central assessment.
    • RemovedHas a local HRD or BRCA test result available. Participants with BRCA-wildtype will have a local HRD test results, as applicable.
    • RemovedHas received up to 6 cycles of standard of care bevacizumab in combination with frontline platinum- based chemotherapy as per approved indication and clinical guidelines and is eligible to continue single agent bevacizumab maintenance per standard of care and investigator discretion.
    • AddedHas HER2 expression.
    • EditedHas a known or suspected deleterious BRCA alteration as per local test that makes the patientparticipant eligible for poly (ADP-ribose) polymerase (PARP) inhibitor.
    • EditedParticipant to receive PARP inhibitor as maintenance per standard of care and investigator discretion. Reasons for which the participant is not eligible for PARP inhibitor will be recorded in the eCRF as follows:
    • RemovedHRD negative
    • RemovedHRD positive with SD as best response after platinum
    • RemovedHRD positive non-serous histology Note: For participants enrolled from the Republic of Korea
    • RemovedHRD tested, but inconclusive
    • RemovedHRD positive but safety concern (safety concern to be specified).
    • RemovedHas a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug products and other monoclonal antibodies.
    • EditedPrevious Cerebralcerebral-Vascular Accidentvascular accident, Transient Ischemic Attacktransient ischemic attack or Sub- Arachnoids Hemorrhagesubarachnoid hemorrhage within 6 months prior to randomization.
    • Edited*Note: For participants enrolled from the Republic of Korea, country-specific requirements are applicable.
    • RemovedHas a history of hemorrhagic disorders, abdominal fistula, gastrointestinal perforation, or active gastrointestinal bleeding within 6 months before randomization.
    • RemovedEvidence of active or ongoing bowel obstruction.
    • RemovedHas a medical history of myocardial infarction within 6 months before randomization, symptomatic congestive heart failure (New York Heart Association Class II to IV).
    • RemovedParticipants with troponin levels above the upper limit of normal at Screening (as defined by the manufacturer), and without any myocardial infarction related symptoms should have a cardiologic consultation during the Screening Period to rule out myocardial infarction.
    • RemovedHas a corrected QT interval prolongation to >480 msec based on average of the Screening triplicate 12-lead ECG.
    • RemovedHas a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
    • AddedHas a history of hemorrhagic disorders.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression Free Survival (PFS) by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
    Secondary outcomes 5 edited, 23 added
    What changed in the outcomes
    • EditedOverall Survival (OS) in the HER2 IHC 3+/2+ populationPopulationTime frame: From date of randomization to death due to any cause, up to approximately 72 months
    • EditedProgression Free SurvivalPFS by BICR in the HER2 IHC 3+/2+/1+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
    • EditedOverall SurvivalOS in the HER2 IHC 3+/2+/1+ populationPopulationTime frame: From date of randomization to death due to any cause, up to approximately 72 months
    • EditedProgression Free SurvivalPFS by the investigatorInvestigator in HER2 IHC 3+/2+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
    • EditedProgression Free SurvivalPFS by the investigatorInvestigator in HER2 IHC 3+/2+/1+ populationPopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
    • AddedProgression Free Survival 2 (PFS2) by the Investigator in HER2 IHC 3+/2+ PopulationTime frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months
    • AddedPFS2 by the Investigator in HER2 IHC 3+/2+/1+ PopulationTime frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months
    • AddedConfirmed Objective Response (OR) by BICR in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
    • AddedConfirmed OR by the Investigator in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
    • AddedConfirmed OR by BICR in HER2 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
    • AddedConfirmed OR by the Investigator in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
    • AddedDuration of Response (DoR) by BICR in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
    • AddedDoR by the Investigator in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 35 months
    • AddedDoR by BICR in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
    • AddedDoR by the Investigator in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 35 months
    • AddedTime to First Subsequent Treatment (TFST) in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 72 months
    • AddedTFST in HER2 IHC 3+/2+/1+ PopulationTime frame: Up to approximately 72 months
    • AddedTime to Second Subsequent Treatment (TSST) in HER2 IHC 3+/2+ PopulationTime frame: Up to approximately 72 months
    • AddedTSST in HER2 3+/2+/1+ PopulationTime frame: Up to approximately 72 months
    • AddedNumber of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 82 months
    • AddedChange from Baseline in Physical Function from European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30)Time frame: Baseline up to approximately 72 months
    • AddedChange from Baseline in Pain from EORTC QLQ-C30Time frame: Baseline up to approximately 72 months
    • AddedChange from Baseline in Global Health Status/Overall Quality of Life (GHS/Overall QoL) Scales from EORTC QLQ-C30Time frame: Baseline up to approximately 72 months
    • AddedChange from Baseline in Abdominal/Gastrointestinal (GI) Symptoms from EORTC Quality of Life Questionnaire Ovarian Cancer Module 28 (QLQ-OV28)Time frame: Baseline up to approximately 72 months
    • AddedPercentage of Participants With Confirmed Deterioration for Physical function, Pain, GHS/Overall QoL scales from EORTC QLQ-C30Time frame: Up to approximately 72 months
    • AddedPercentage of Participants With Confirmed Deterioration Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28Time frame: Up to approximately 72 months
    • AddedTime to Confirmed Deterioration for Physical Function, Pain, GHS/Overall QoL Scales from EORTC QLQ-C30Time frame: Up to approximately 72 months
    • AddedTime to Confirmed Deterioration for Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28Time frame: Up to approximately 72 months
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06819007
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Mar 19, 2025
Primary completion
Nov 1, 2028 (estimated)
Completion
Jan 31, 2032 (estimated)
Last update
Oct 28, 2026

Study contacts

Contact for Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion